CDC37 as a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

Blood Cancer Journal - United States
doi 10.1038/s41408-019-0171-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

ALK-negative Anaplastic Large Cell Lymphoma

2020English

Reactive Oxygen Species and Lipoxygenases Regulate the Oncogenicity of NPM-ALK-positive Anaplastic Large Cell Lymphomas

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

Leukemic Phase of ALK-positive Anaplastic Large Cell Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2013English

Alk Expression Plays Different Roles in Anaplastic Large-Cell Lymphomas and Outcome of Crizotinib Use in Relapsed/Refractory Alk+ Patients in a Chinese Population

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Secondary CNS Involvement of ALK-negative Anaplastic Large Cell Lymphoma

American Journal of Hematology
Hematology
2017English

Prognostic Significance of NPM-ALK Fusion Transcript Overexpression in ALK-positive Anaplastic Large-Cell Lymphoma

Modern Pathology
Forensic MedicinePathology
2007English

Intravascular ALK-Positive Anaplastic Large-Cell Lymphoma Mimicking Inflammatory Breast Carcinoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Constitutive Control of AKT1 Gene Expression by JUNB/CJUN in ALK+ Anaplastic Large-Cell Lymphoma: A Novel Crosstalk Mechanism

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

Breast Implant‐associated Anaplastic Large Cell Lymphoma and Other Rare T‐cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy